Research progress of B cell receptor pathway inhibitors in the treatment of chronic lymphocytic leukemia:reports from the 57th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2016.03.002
- VernacularTitle:B细胞受体通路抑制剂在慢性淋巴细胞白血病治疗中的研究进展：第57届美国血液学会年会报道
- Author:
Qian SUN
;
Wei XU
;
Jianyong LI
- Publication Type:Journal Article
- Keywords:
Leukemia,lymphocytic,chronic;
B cell receptor pathway;
Inhibitors;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2016;25(3):134-138
- CountryChina
- Language:Chinese
-
Abstract:
With the recent success of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, and the phosphoinositide-3-kinase (PI3K) inhibitor idelalisib in the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL), a number of new agents targeting the B cell receptor (BCR) pathway are in clinical development. In the 57th American Society of Hematology (ASH) annual meeting, great interests are still focused on these two drugs, either monotherapy or combination in the treatment of CLL. On the other hand, SYK inhibitors, new BTK and PI3K antagonists are also coming to the forefront, casting a new light on the treatment of ibrutinib/idelalisb-resistant patients. The progresses of BCR pathway inhibitors in CLL will be summarized in this paper based on the reports in the 57th ASH annual meeting.
